Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company whose news flow centers on the development of its INTASYL® gene silencing technology and lead compound PH-762. Company announcements describe INTASYL as a gene silencing platform focused on immuno-oncology therapeutics, with PH-762 targeting the PD-1 gene implicated in various forms of skin cancer.
News about Phio frequently covers clinical trial milestones for PH-762. The company has reported completion of enrollment in its ongoing Phase 1b dose escalation trial (NCT 06014086), interim pathology results in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and safety reviews by its Safety Monitoring Committee. Updates have included detailed response rates, such as complete, near complete, and partial responses based on tumor clearance, as well as statements that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed in the cohorts reported.
Phio also issues regulatory and development updates, including acceptance by the U.S. Food and Drug Administration of its nonclinical protocol study design for a toxicology study required before a pivotal trial of PH-762. Additional news items describe agreements with a U.S. manufacturer for cGMP clinical supply of PH-762 and progress toward delivering commercially viable drug product.
Investors following PHIO news will also see financing and corporate announcements, such as warrant inducement transactions, cash runway commentary, and board-level changes, including the appointment of a Lead Independent Director. The company regularly participates in investor conferences and scientific meetings, where it presents INTASYL technology and PH-762 data, and has highlighted external recognition such as PH-762 being named “Immunomodulatory Solution of the Year” in the BioTech Breakthrough Awards.
This news page aggregates these clinical, regulatory, financing, and governance updates so readers can track how Phio’s INTASYL platform and PH-762 program are progressing over time.
Phio Pharmaceuticals (NASDAQ: PHIO) announced positive results from the second cohort of its Phase 1b clinical trial evaluating PH-762 for treating various skin cancers. The Safety Monitoring Committee (SMC) recommended proceeding to the third dose cohort following encouraging safety data. The second cohort, comprising 4 patients with cutaneous squamous cell carcinoma, showed promising results with the first two patients achieving complete response (100% tumor clearance) and partial response (90% clearance) at Day 36. The intratumoral injections were well-tolerated with no dose-limiting toxicities or serious adverse events reported.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the publication of their research on PH-762, their INTASYL® siRNA compound, in Frontiers in Immunology. The article presents preclinical proof-of-concept data for PH-762, designed to silence PD-1 for cancer treatment. Recent Phase 1b clinical trial data showed promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in cutaneous squamous cell carcinoma treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) has been nominated as a finalist for the Technology Disruptor of the Year award at Advanced Therapies Week 2025 in Dallas. The nomination highlights their patented INTASYL technology, a siRNA gene silencing platform designed to enhance immune cells' cancer-fighting capabilities.
Recent clinical data from their Phase 1b study of INTASYL compound PH-762 showed promising results, with one cutaneous squamous cell carcinoma patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance). The award ceremony will take place January 20-23, 2025, featuring judges from H.C. Wainwright & Co., Gama Biosciences, and Propel Biosciences.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for developing therapeutics using INTASYL® siRNA gene silencing technology to enhance immune cells' cancer-fighting capabilities, will have CEO and Chairman Robert Bitterman present on Tuesday, December 10, 2024, at 12:00 pm EST. Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website.
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in the second dose cohort. The study evaluates PH-762, an INTASYL compound that silences PD-1, in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2024 financial results and provided updates on its Phase 1b clinical trial for PH-762. The trial's second cohort is fully enrolled, showing promising early results with one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in cutaneous squamous cell carcinoma patients. Financial highlights include cash position of $5.4 million as of September 30, 2024, reduced R&D expenses of $0.6 million (down 64% YoY), and a narrowed net loss of $1.5 million compared to $2.8 million in Q3 2023. The company raised approximately $2.6 million through warrant exercises in July 2024.
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patients in Cohorts 1 and 2.
Notable outcomes include one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in patients with cutaneous squamous cell carcinoma in the second cohort. The trial, expected to complete enrollment by Q3 2025, demonstrates promising results in making immune cells more effective at killing cancer cells using INTASYL® siRNA technology.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announces its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for its INTASYL® siRNA gene silencing technology aimed at enhancing immune cells' cancer-fighting capabilities, will have CEO and Board Chairman Robert Bitterman present on Thursday, November 7 at 12:00 pm EST.
Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website. The presentation focuses on Phio's innovative approach to creating new pathways towards a cancer-free future through their proprietary technology.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced it will present new clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX from November 8-10, 2024. The presentation, titled 'INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma,' will be delivered by Dr. Mary Spellman on November 9, 2024. The company's proprietary INTASYL siRNA gene silencing technology is designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced a correction to the registration link for their upcoming presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, featuring CEO and Chairman Robert Bitterman, is scheduled for Wednesday, October 23, 2024, at 12 PM EDT.
Stakeholders, investors, and other interested parties are invited to register and attend this live event. The presentation will include a live Q&A session. A replay of the event will be available on the Renmark Financial Communications Inc. website. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.